Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

By V. Gebski, B. Burmeister, B. Smithers, K. Foo, J. Zalcberg, J. Simes. The Lancet Oncology, 2007

1,170 citations recorded by the source corpus.

Subfields: Oncology, Otorhinolaryngology, Surgery

View Paper: https://www.semanticscholar.org/paper/3565d751edbae8637a3933b4472d553295ea3786

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Mathieu Hatt
2. F. Tixier
3. C. L. Le Rest
4. Dimitris Visvikis
5. N. Albarghach
6. O. Pradier
7. J. Metges
8. L. Corcos

Citations in the corpus

• Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, background): “The extent of this benefit was smaller for patients with T2 tumours [20].”
• A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) (2011, background): “patients with adenocarcinoma, but not in patients with squamous cell carcinoma.(17)”
• Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer (2011, background): “In locally advanced esophageal cancer, preoperative chemotherapy or radiochemotherapy will improve survival in patients who respond to induction therapy (1,2).”